Guizhou Sanli Pharmaceutical Co., Ltd. Class ASSE: 603439

Announcement on Progress in Drug Marketing Authorization Transfer

Jun 9, 2026 · Issued by Guizhou Sanli Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Progress in Drug Marketing Authorization Transfer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Guizhou Sanli Pharmaceutical Co., Ltd. Class A

Announcement on Resolutions of the 24th Meeting of the 4th Board of DirectorsMay 26
Announcement on Resolutions of the 2025 Annual General MeetingMay 21
Announcement on the Holding of 2026 Collective Reception Day Activities for Investors of Listed Companies in Guizhou Jurisdiction and Outline of the 2025 Annual Performance BriefingMay 13
Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Guizhou Jurisdiction and 2025 Annual Performance Briefing and Soliciting QuestionsApr 28

All Guizhou Sanli Pharmaceutical Co., Ltd. Class A news releases